Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression
Open accessPublished version of a preprint
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Abstract Purpose: VEGF-targeted therapies have modest efficacy in cancer patients, but acquired resistance is common. The mechanisms underlying such resistance are poorly understood. Experimental Design: To evaluate the potential role of immune cells in the development of resistance to VEGF blockade, we first established a preclinical model of adaptive resistance to anti-VEGF therapy. Additional in vitro and in vivo studies were carried out to characterize the role of macrophages in such resistance. Results: Using murine cancer models of adaptive resistance to anti-VEGF antibody (AVA), we found a previously unrecognized role of macrophages in such resistance. Macrophages were actively recruited to the tumor microenvironment and were responsible for the emergence of AVA resistance. Depletion of macrophages following emergence of resistance halted tumor growth and prolonged survival of tumor-bearing mice. In a macrophage-deficient mouse model, resistance to AVA failed to develop, but could be induced by injection of macrophages. Downregulation of macrophage VEGFR-1 and VEGFR-3 expression accompanied upregulation of alternative angiogenic pathways, facilitating escape from anti-VEGF therapy. Conclusions: These findings provide a new understanding of the mechanisms underlying the modest efficacy of current antiangiogenesis therapies and identify new opportunities for combination approaches for ovarian and other cancers. Clin Cancer Res; 23(22); 7034–46. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the accumulation of immunosuppressive cells, including TAMs, has been linked with resistance to VEGFA-targeting antibodies in mouse models of ovarian cancer”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Dalton et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase
Minokoshi, Y., Kim, Y.-B., Peroni, O. D., Fryer, L. G. D., Müller, C., Carling, D., & Kahn, B. B. (2002) · Nature · doi:10.1038/415339a · Cited by 2,053
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Mitchem, J. B., Brennan, D. J., Knolhoff, B. L., Belt, B. A., Zhu, Y., Sanford, D. E., Belaygorod, L., Carpenter, D., Collins, L., Piwnica-Worms, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2731 · Cited by 943
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.008 · Cited by 864
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
“Monocytes and macrophages promote resistance to anti-VEGF therapy by altering VEGF receptor expression (Dalton et al., 2017) or inhibiting adaptive immunity (Jung et al.”
BackgroundMacrophage Polarization States in the Tumor Microenvironment
Boutilier, A. J., & Elsawa, S. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136995 · Cited by 1,631
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Martinez, M., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 851
Targeting VEGF/VEGFR to modulate antitumor immunity
Yang, J., Yan, J., & Liu, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00978 · Cited by 646
“The resistance to anti-VEGF failed to occur in a macrophagedeficient mouse model (95).”
Background
Metadata
- Authors
- Dalton, H. J., Pradeep, S., McGuire, M., Hailemichael, Y., MA, S., Lyons, Y., Armaiz-Pena, G. N., Previs, R. A., Hansen, J. M., Rupaimoole, R., Gonzalez-Villasana, V., Cho, M. S., Wu, S. Y., Mangala, L. S., Jennings, N. B., Hu, W., Langley, R., Mu, H., Andreeff, M., Bar-Eli, M., Overwijk, W., Ram, P., Lopez-Berestein, G., Coleman, R. L., & Sood, A. K.
- Affiliations
- 1Departments of Gynecologic Oncology and Reproductive Medicine,
- Medical College of Wisconsin (US)
- 3Department of Melanoma Medical Oncology,
- 4Experimental Therapeutics,
- The University of Texas MD Anderson Cancer Center (US)
- 8Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- Corresponding author
- Sood, Anil K.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2017-11-14
- Volume
- 23
- Issue
- 22
- Pages
- 7034-7046
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC5690831
- OpenAlex
- W2751214182
- Cited by
- 97
- References
- 31
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 11 · 2023: 11 · 2022: 15 · 2021: 14 · 2020: 12 · 2019: 10 · 2018: 9
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- El Repositorio Academico Digital de la UANL (Universidad Autónoma de Nuevo León) (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UH3TR000943)
- National Cancer Institute (R35CA209904, P50CA098258, U01CA213759, R01CA109298, P50CA083639, P30CA016672, T32CA101642)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- macrophages, anti-VEGF therapy resistance, VEGFR1, VEGFR-3, adaptive resistance, anti-angiogenic therapy, tumor microenvironment, macrophage recruitment, ovarian cancer, combination therapy
- MeSH terms
- Animals, Antineoplastic Agents, Cell Survival, Disease Models, Animal, Female, Humans, Macrophages, Neoplasms, Neovascularization, Pathologic, Promoter Regions, Genetic, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Receptors, Vascular Endothelial Growth Factor, Cell Line, Tumor, Cell Proliferation, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-0647
- The paper
- Dalton, H. J., Pradeep, S., McGuire, M., Hailemichael, Y., MA, S., Lyons, Y., Armaiz-Pena, G. N., Previs, R. A., Hansen, J. M., Rupaimoole, R., Gonzalez-Villasana, V., Cho, M. S., Wu, S. Y., Mangala, L. S., Jennings, N. B., Hu, W., Langley, R., Mu, H., Andreeff, M., . . . Sood, A. K. (2017). Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-0647
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.